Skip to main content

Table 1 Patient baseline demographics; safety set

From: Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients

  Dose-titration phase (n= 39) Parallel-group phase
Lanthanum carbonate (n= 10) Placebo (n= 11)
Sex, n (%)    
  Male 30 (76.9) 6 (60.0) 8 (72.7)
  Female 9 (23.1) 4 (40.0) 3 (27.3)
Ethnicity, n (%)    
  Asian 1 (2.6) 0 (0.0) 0 (0.0)
  Caucasian 38 (97.4) 10 (100.0) 11 (100.0)
Age, yearsa 53.4 (15.6) 51.5 (17.5) 54.4 (15.3)
Duration of renal disease, yearsb 5.0 (1.0-41.0) 4.0 (1.0-21.0) 9.0 (1.0-41.0)
Duration of dialysis, monthsb 17.0 (6.0-107.0) 11.0 (6.0-87.0) 13.0 (6.0-107.0)
Previous transplant, n (%) 8 (20.5) 2 (20.0) 3 (27.3)
  1. aMean (standard deviation).
  2. bMedian (minimum, maximum).